Contaminated Medical Product Alert N°4/2023
GUAIFENESIN SYRUP TG SYRUP: contaminated product alert
WHO issued this alert on a guaifenesin cough syrup reported to WHO on 6 April 2023. Samples from the Marshall Islands analysed by the quality control laboratories of the Therapeutic Goods Administration of Australia contained unacceptable amounts of diethylene glycol and ethylene glycol. WHO said the product may have marketing authorisations elsewhere in the Western Pacific region.1,2
- Issued
- 25 April 2023
- Issued by
- World Health Organization
- Name stated on packaging
- QP Pharmachem Ltd (Punjab, India), the stated manufacturer, with Trillium Pharma (Haryana, India) as stated marketer
- Genuine manufacturer's statement
- WHO said neither the stated manufacturer nor the marketer had provided guarantees to WHO on the safety and quality of these products.
- Countries where detected
- Marshall Islands, Micronesia (Federated States of)
Batches named in the alert
SL-429 (expiry 10/2023)
Advice as stated
Do not use the affected products. Anyone who used them and had an adverse reaction should seek medical advice. Report suspected adverse events to the national regulatory authority or pharmacovigilance centre.
Names printed on falsified products are not evidence that the named company made them. Where WHO or a regulator reports the genuine manufacturer's statement, it is shown.
Sources
- World Health Organization, Medical Product Alert N°4/2023: Substandard (contaminated) syrup medicines (25 April 2023)
- World Health Organization, Medical Product Alert N°4/2023: annex (PDF) (25 April 2023)